Loading clinical trials...
Loading clinical trials...
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Conditions
Interventions
Cx601
Placebo
Locations
159
United States
Scottsdale Mayo Clinic
Scottsdale, Arizona, United States
UC San Diego Health Systems
La Jolla, California, United States
University of Southern California (USC) Norris Comprehensive Cancer Center
Los Angeles, California, United States
UC Irvine Medical Center - Chao Family Comprehensive Cancer
Orange, California, United States
Inland Empire Liver Foundation
Rialto, California, United States
Kaiser Permamente
San Francisco, California, United States
Start Date
September 15, 2017
Primary Completion Date
January 23, 2023
Completion Date
July 26, 2023
Last Updated
September 19, 2024
NCT06226883
NCT07184931
NCT06918808
NCT06647615
NCT07377188
NCT07385131
Lead Sponsor
Tigenix S.A.U.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions